top of page
HR+/HER2− Breast Cancer (Hormone Receptor-Positive, HER2-Negative): Treatment at Every Stage — 2026 Guideline Update

HR+/HER2− Breast Cancer (Hormone Receptor-Positive, HER2-Negative): Treatment at Every Stage — 2026 Guideline Update

ป้าหมอนุช
12 hours ago
8 min read

HR+/HER2− breast cancer is breast cancer whose cells are positive for estrogen and/or progesterone receptors (hormone receptor–positive) but do not overexpress the HER2 protein. It is the most common type, accounting for about 7 in 10 breast cancers. The backbone of treatment is endocrine (anti-hormone) therapy, combined with surgery, radiation and other drugs according to the risk of recurrence. At Namarak Hospital, our team plans treatment according to the latest 2026 NCCN, ASCO and ESMO guidelines.

This article summarizes treatment of hormone receptor–positive, HER2-negative breast cancer from early stage and locally advanced disease to recurrence and metastatic disease, so that patients and families can understand their options and talk with their doctors confidently.

What is HR+/HER2−, and how to read the pathology report

After a biopsy or surgery, the pathologist performs special stains (immunohistochemistry) for four key markers: estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67, which reflects how fast the cells are dividing.

  • ER and/or PR positive — the cancer depends on hormones to grow and therefore responds to endocrine therapy

  • HER2 negative — no HER2 overexpression (IHC 0, 1+, or 2+ with negative ISH), so classic HER2-targeted drugs are not used

  • HER2-low / HER2-ultralow — subgroups of HER2-negative disease that still carry low levels of HER2; important in metastatic disease because they open the door to antibody–drug conjugates (ADCs). See HER2-low and HER2-ultralow

  • ER-low (1–10%) — behaves much like triple-negative disease; the 2026 ASCO guideline states it may be treated like TNBC

Together with tumor size, lymph node involvement, grade, age and menopausal status, these results are used to estimate the "risk of recurrence", which determines how much additional treatment is needed.

Overview of early-stage HR+/HER2− treatment (stage I–III)

The ASCO Living Guideline version 2026.1.0 (published August 2026) emphasizes "matching the level of treatment to each person's true risk": people at low risk should not receive more drugs than they need, and people at high risk should receive the full set of add-on treatments, with endocrine therapy as the backbone for almost everyone.

1. Surgery

  • Breast-conserving surgery with radiation gives survival equivalent to mastectomy in appropriately selected patients

  • Mastectomy, with or without breast reconstruction, depending on tumor size, location and the patient's preference

  • Axillary lymph nodes — most patients have a sentinel lymph node biopsy instead of a full axillary dissection; in selected postmenopausal patients with small tumors and a normal axillary ultrasound, the SOUND and INSEMA trials suggest axillary surgery may be omitted altogether

2. Radiation therapy

After breast-conserving surgery, most patients need radiation to reduce the risk of local recurrence. Eligible patients may receive intraoperative radiotherapy (IORT), completed in a single session, based on the TARGIT-A trial. Older patients (generally 65–70 years and above) with small, node-negative tumors who complete endocrine therapy may consider omitting radiation, based on their doctor's assessment together with the patient's own decision.

3. Adjuvant endocrine therapy — the backbone of treatment

  • Postmenopausal: an aromatase inhibitor (AI) is the main option; tamoxifen can be used if an AI is not tolerated or in the presence of osteoporosis

  • Premenopausal: tamoxifen alone, or ovarian function suppression (OFS) combined with tamoxifen or an AI; the 2026 ASCO guideline recommends OFS plus an AI for higher-risk patients

  • Duration: at least 5 years, extended up to 10 years when the long-term risk of recurrence remains high; tools such as CTS5 or the Breast Cancer Index may help with this decision

Taking the medication continuously for the full course is very important. If side effects such as hot flushes or joint pain occur, tell your doctor so the treatment can be adjusted.

4. Chemotherapy — who needs it and who does not

Many patients with HR+/HER2− disease do not need chemotherapy. The decision combines clinical information with genomic testing of the tumor, such as Oncotype DX or MammaPrint, which shows whether chemotherapy would truly add benefit. In 2026, NCCN also endorses MammaPrint/BluePrint to help decide whether an anthracycline chemotherapy is needed. When chemotherapy is required, the regimen is chosen according to risk and other medical conditions, especially heart disease.

5. Add-on treatments for higher-risk disease

  • CDK4/6 inhibitors with endocrine therapy — abemaciclib for 2 years for stage II–III disease with ≥4 positive nodes, or 1–3 positive nodes with high-risk features (monarchE trial), and ribociclib for 3 years for stage II–III disease, including some high-risk node-negative patients (NATALEE trial); 6-year data presented at ESMO 2026 showed an overall survival benefit (HR 0.81)

  • Olaparib for 1 year for patients with an inherited BRCA1/2 mutation (or PALB2 per ASCO 2026) and high-risk disease, after completing chemotherapy and surgery. See BRCA genes and family history

  • Bisphosphonates in selected postmenopausal patients, to reduce bone recurrence and protect bone density during AI therapy

ASCO 2026 uses the "10-year risk of breast cancer death" to guide CDK4/6 inhibitor use: recommended when the risk is above 25%, considered individually at 10–25%, and generally not recommended below 10%. These drugs do not replace chemotherapy in patients who need it.

Locally advanced disease (stage III) and treatment before surgery

When the tumor is large or has spread to many lymph nodes, the doctor may give drugs before surgery (neoadjuvant therapy) to shrink the tumor, increase the chance of breast conservation and assess how the disease responds.

  • Neoadjuvant chemotherapy — for higher-risk or locally advanced disease

  • Neoadjuvant endocrine therapy — an option for postmenopausal patients who do not need chemotherapy; it usually takes several months to reach full effect, and is generally not recommended outside clinical trials for premenopausal patients

  • Immunotherapy — the KEYNOTE-756 trial increased the pathologic complete response (pCR) rate in high-risk disease, but long-term survival data are awaited, so it is not yet standard for HR+ disease in general

After neoadjuvant treatment, patients proceed to surgery, radiation and endocrine therapy, plus the risk-adapted add-on treatments described above.

Follow-up and local recurrence

A distinctive feature of HR+ cancer is that it can recur even more than 5–10 years later, so regular follow-up and completing endocrine therapy are essential. Standard follow-up consists of history and physical examination and a yearly mammogram; whole-body scans are not needed in the absence of symptoms.

If the cancer returns in the breast, chest wall or regional lymph nodes (locoregional recurrence), the doctor will confirm it with a biopsy and re-test the receptors, look for distant spread, and treat with surgery, radiation (if not previously given to that area) and drugs according to the tumor type. Many of these patients can still be cured.

Metastatic HR+/HER2− breast cancer (stage IV): biomarker-driven treatment

Although metastatic disease is usually not curable, many patients now live with well-controlled disease for years with good quality of life. The principle is to use endocrine therapy combined with targeted drugs for as long as possible before moving to chemotherapy, except in visceral crisis. When metastasis is first diagnosed, a biopsy should confirm it and the receptors should be re-tested.

First-line treatment

  • An AI plus a CDK4/6 inhibitor is standard; NCCN (Version 4.2026) lists ribociclib as category 1, and ESMO 2026 ranks the preference as ribociclib, abemaciclib, palbociclib

  • If the cancer recurs during or within 12 months after adjuvant endocrine therapy, use fulvestrant plus a CDK4/6 inhibitor

  • With a PIK3CA mutation and early relapse after adjuvant endocrine therapy, use inavolisib + palbociclib + fulvestrant

  • Premenopausal patients also need ovarian suppression

ESR1 testing during treatment (ctDNA monitoring)

ESR1 mutations often develop during AI therapy and cause resistance. In the SERENA-6 trial, blood tests for ESR1 (ctDNA) were repeated regularly, and switching from the AI to camizestrant as soon as an ESR1 mutation appeared — before the disease progressed — extended progression-free survival from 9.2 to 16.8 months. The US FDA granted accelerated approval in September 2026. This approach is still debated regarding testing frequency and cost, and your doctor will consider it individually.

Second line and beyond — choosing drugs by biomarker

  • ESR1 mutation: new oral endocrine drugs (oral SERDs/PROTAC) — elacestrant, imlunestrant and vepdegestrant (FDA approval May 2026)

  • PIK3CA, AKT1 or PTEN alteration: capivasertib + fulvestrant, or alpelisib + fulvestrant (for PIK3CA)

  • PIK3CA wild-type: gedatolisib + fulvestrant ± palbociclib (FDA approval July 2026)

  • Inherited BRCA1/2 mutation: olaparib or talazoparib

  • No specific biomarker: everolimus with endocrine therapy, or switching CDK4/6 inhibitor with fulvestrant

Antibody–drug conjugates (ADCs)

  • Trastuzumab deruxtecan (T-DXd) for HER2-low and HER2-ultralow disease after endocrine therapy (NCCN: after at least 1 line; ESMO 2026: after at least 2 lines, or earlier with rapid endocrine resistance); requires monitoring for drug-induced pneumonitis

  • Datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan after at least 1 line of chemotherapy

  • The best sequence of ADCs is not yet established; the doctor will choose according to HER2 level, previous treatments and side effects

Important note: several of these new drugs are approved in the US or Europe but may not yet be registered or available in Thailand, and reimbursement varies. Our team will explain the options that are actually available and the estimated costs.

Alongside drug treatment, supportive care — such as bone-strengthening drugs for bone metastases, palliative radiation for pain, and psychological support — helps maintain quality of life throughout treatment.

Summary of HR+/HER2− treatment by stage

  • Early stage, low risk: surgery + radiation (omitted in some) + endocrine therapy for 5 years or more; most do not need chemotherapy

  • Early stage, intermediate risk: genomic testing guides the chemotherapy decision; consider OFS in premenopausal patients

  • Stage II–III, high risk: chemotherapy + endocrine therapy + CDK4/6 inhibitor, and olaparib if BRCA-mutated

  • Local recurrence: confirm by biopsy, surgery/radiation and systemic therapy — cure is still possible

  • Metastatic: endocrine therapy + CDK4/6 inhibitor first line, monitor ESR1, then biomarker-matched drugs and ADCs

Frequently asked questions (FAQ)

Can HR+/HER2− breast cancer be cured?

Early-stage disease (I–III) has a high chance of cure, especially when endocrine therapy is completed as planned. Metastatic disease is usually not curable, but can now be controlled for many years with endocrine therapy combined with targeted drugs.

Does everyone with HR+/HER2− need chemotherapy?

No. Many patients, especially those at low risk, gain no added benefit from chemotherapy. Doctors use tumor size, nodes, grade, age and genomic tests such as Oncotype DX or MammaPrint to decide.

How long do I need to take endocrine therapy?

At least 5 years, and up to 10 years for those with a high long-term risk of recurrence. Stopping early on your own increases the risk of recurrence; if you have side effects, talk to your doctor about adjusting treatment rather than stopping.

What are CDK4/6 inhibitors, and who should receive them?

They are oral drugs that block cancer cell division and are used with endocrine therapy. In early-stage disease they are used for patients at high risk of recurrence, such as those with several positive lymph nodes; in metastatic disease they are standard first-line treatment. Side effects to monitor include low white cell counts, diarrhea and liver tests.

I am still having periods — do I need ovarian suppression injections?

It depends on the risk. Lower-risk patients may take tamoxifen alone, while higher-risk patients benefit from ovarian suppression combined with tamoxifen or an AI. Those who wish to have children in the future should discuss fertility preservation before starting treatment.

What is ESR1 testing, and do I need it?

It tests for mutations in the estrogen receptor gene, usually from a blood sample (ctDNA), in metastatic disease, to choose new endocrine drugs that work against ESR1 mutations. ESMO 2026 recommends testing when the disease progresses on an AI.

Are newly approved drugs available in Thailand?

Some are already available in Thailand and some are not yet registered. Our team will explain the options that are actually available and help coordinate insurance coverage or access to medicines.

About Namarak Hospital

Namarak Hospital is a specialized breast hospital in Bangkok, where breast surgeons, medical oncologists, radiologists and pathologists plan treatment together as a multidisciplinary team according to the latest international guidelines. To discuss a treatment plan or request a second opinion, see Breast Cancer Treatment, Second Opinion, or contact us on LINE, tel. +66 2 059 0245.

Related treatment guides by cancer type

References

  • NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 4.2026 (JNCCN 2026;24(7))

  • Caswell-Jin JL, et al. Medical Therapy for HR+/HER2− Stage I–III Breast Cancer: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol 2026

  • de Azambuja E, et al. Metastatic breast cancer: ESMO Clinical Practice Guideline. Ann Oncol 2026;37(9)

  • NATALEE 6-year analysis, ESMO Congress 2026 (LBA25)

  • SERENA-6 (camizestrant); FDA accelerated approval, September 2026

  • VERITAC-2 (vepdegestrant); FDA approval, May 2026 · VIKTORIA-1 (gedatolisib); FDA approval, July 2026

Medically reviewed by: Namarak Hospital medical team · Guidelines checked: 16 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.

Comments


Link to the Namarak Hospital medical team profiles
bottom of page